UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

PATENT NO. : 5,521,184
ISSUED : May 28, 1996
INVENTOR : Jürg Zimmerman
PATENT OWNER : NOVARTIS CORPORATION
PRODUCT : Gleevec® (imatinib mesylate)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 5,521,184 based upon the regulatory review of the product Gleevec® (imatinib mesylate) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

586 days

from May 28, 2013, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).

I have caused the seal of the United States Patent and Trademark Office to be affixed this 7th day of January 200

JAMES E. ROGAL
Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office